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Abstract
Insulin resistance is considered to be a pathogenetic mechanism in several and diverse dis-
eases (e.g. type 2 diabetes, atherosclerosis) often antedating them in apparently healthy
subjects. The aim of this study is to investigate with a microarray based approach whether
IR per se is characterized by a specific pattern of gene expression. For this purpose we ana-
lyzed the transcriptomic profile of peripheral blood mononuclear cells in two groups (10 sub-
jects each) of healthy individuals, with extreme insulin resistance or sensitivity, matched for
BMI, age and gender, selected within the MultiKnowledge Study cohort (n = 148). Data were
analyzed with an ad-hoc rank-based classification method. 321 genes composed the gene
set distinguishing the insulin resistant and sensitive groups, within which the “Adrenergic
signaling in cardiomyocytes” KEGG pathway was significantly represented, suggesting a
pattern of increased intracellular cAMP and Ca2+, and apoptosis in the IR group. The same
pathway allowed to discriminate between insulin resistance and insulin sensitive subjects
with BMI >25, supporting his role as a biomarker of IR. Moreover, ASCM pathway harbored
biomarkers able to distinguish healthy and diseased subjects (from publicly available data
sets) in IR-related diseases involving excitable cells: type 2 diabetes, chronic heart failure,
and Alzheimer’s disease. The altered gene expression profile of the ASCM pathway is an
early molecular signature of IR and could provide a common molecular pathogenetic plat-
form for IR-related disorders, possibly representing an important aid in the efforts aiming at
preventing, early detecting and optimally treating IR-related diseases.
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Introduction
Insulin resistance (IR), operationally defined as a reduction in insulin-mediated glucose
metabolism [1], is commonly associated with obesity [2], ageing [3], male gender [4] and phys-
ical inactivity [5], and precedes and predicts Type 2 Diabetes Mellitus (T2DM) [6]. In the early
stage, the euglycemic state is maintained by compensatory hyperinsulinemia [7], so that early
alterations in insulin signaling at the cellular level may occur also in apparently healthy sub-
jects [8]. The consequences of chronic IR/hyperinsulinemia are believed to be far reaching,
and not limited to T2DM pathogenesis [6], but also to other conditions, including atherogenic
dyslipidemia [9], hypertension [10] and atherosclerosis itself [11, 12]. This has been encapsu-
lated in the concept of metabolic syndrome [13, 14], or cardiometabolic risk [15], a clinically
recognizable high risk state for T2DM and cardiovascular disease, which are believed to be
pathogenically rooted in the common soil of IR [14, 15]. The list of other conditions associated
with IR is impressively long and diverse, and includes, without being limited to, Alzheimer’s
disease (AD) [16] and chronic heart failure (CHF) [17, 18].
The early molecular alterations leading to IR in humans are known only in part. One well
grounded hypothesis holds that increased diacylglycerol and activation of several protein kin-
ase Cs are central to the development of IR in a number of conditions such as obesity, T2DM,
non alcoholic fatty liver disease, and have been detected also in lean old individuals and lean
first degree relatives of patients with T2DM [19]. However, this scenario might be unable to
explain why, for instance, in some individuals, pancreatic beta cells fail to compensate IR and
T2DM develops [20], i.e. it may need a second “hit” to account for the dire consequences of
IR. Another hypothesis, supported by a wealth of convincing experimental evidences, puts
FOXO proteins, in particular FOXO1, at the heart of the pathogenesis of both liver/hypothala-
mus IR and beta cell demise [21, 22]. However, FOXO1 emerges as a key transducer to most,
but perhaps not all [23], detrimental consequences of IR, leaving unanswered the question of
what causes IR in the first place. Of course the combination of the two hypotheses would be
endowed with fully explanatory power, according to a “plural pathway” mechanism.
Both the above mentioned hypotheses are extensions of working hypotheses [24, 25] aiming
at explaining findings in a single, specific organ known to be involved in the pathogenesis of
IR and T2DM. However, in the case of heterogeneity/multiplicity of the mechanisms of IR, by
focusing at the beginning on a single tissue there might be an inadvertent selection bias in
favor of pathogenetic mechanisms preferentially and/or primarily at work in that tissue and
against possible generalized, widespread mechanism(s).
Peripheral blood mononuclear cells (PBMCs) express approximately 80% of the genes
encoded by the human genome [26]. Furthermore, the continuous contact of PBMCs with
both endogenous and exogenous cues puts them in a unique position to recapitulate the overall
genomic response of the individual to the environment. Thus, PBMC gene expression profile
may be a useful, accessible window on the pathophysiology of processes occurring in hardly
accessible organs and tissues [27]. A few studies of PBMC gene expression analysis have been
performed to detect cross-sectionally the associations with dietary patterns in healthy individ-
uals or to monitor the changes induced by dietary intervention in obese, insulin-resistant indi-
viduals [28–31].
We hypothesized that, if IR induces ubiquitous changes in gene expression patterns,
circulating mononuclear cells may be reporters of this phenomenon. The aim of our study,
therefore, was to assess whether “primary” (i.e. not associated to obesity and/or metabolic syn-
drome) IR is characterized by a specific pattern of gene expression profile in PBMCs. To reach
this goal, we analyzed 40 healthy subjects in two different comparisons. Initially, we selected
20 lean healthy individuals from the extremes of the distribution of HOMA-IR (Homeostasis
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Model Assessment-estimated Insulin Resistance), a recognized and widely used index of IR
[32], within a cohort of carefully phenotyped healthy subjects, after matching for BMI (Body
Mass Index), age and sex. In these two polar groups, with a hugely different degree of insulin
sensitivity, we explored, with a microarray based approach, the gene expression profile of
PBMC by an innovative rank-based classification method [33, 34] and we discovered a bio-
marker of “primary” IR. After identifying a specific pathway as the putative originator of the
biomarker of “primary” IR, we tested further whether alterations in gene expression of this
pathway could be considered as a biomarker of IR. As a first step, we tested whether the ASCM
pathway tracks with insulin resistance also in 20 otherwise healthy overweight/obese people.
Secondly, we investigated whether the same pathway could represent a biomarker of organ
damage related to IR, by testing its expression pattern in clinical IR-related disorders, such as
T2DM [35], CHF [36, 37] and AD [38] (from publicly available data sets).
Results
Characteristics of the study population
The main features of the whole study cohort are reported in S1 Table. All subjects had normal
glucose regulation, with fasting plasma glucose <100mg/dl and 2h plasma glucose after
OGTT < 140mg/dl (ADA guidelines). The insulin-sensitive (IS) and the insulin-resistant (IR)
groups were selected from the entire cohort as described in the Methods section. The main
characteristics of the IS (n = 10) and of the IR (n = 10) groups are reported in Table 1. No sta-
tistically significant differences in the variables composing the metabolic syndrome/cardiome-
tabolic risk (glucose, waist, blood pressure, triglycerides and HDL-cholesterol) were detected
between the IS and the IR groups. The IR group, however, had a mean homeostatic model
assessment (HOMA)-IR value 8-fold higher than the IS group (p<0.001), to highlight a huge
difference in insulin sensitivity.
Gene expression microarray analysis: identification of a biomarker of
insulin sensitivity/resistance
The biomarker computation was carried out by an enhanced version of the rank-based classifi-
cation method introduced in [32, 33] as described in the Methods section. The IS and IR
groups of subjects could be distinguished by a biomarker of 512 probes with an accuracy of
Table 1. Anagraphic, anthropometric and clinical characteristics of the low BMI insulin-sensitive (Low HOMA-IR) and insulin-resistant (High
HOMA-IR) groups. N.s.: non-significant.
Low HOMA-IR High HOMA-IR p-value
Gender (M/F) (n) 7/3 7/3 n.s.
Age (years) 40.2 ± 11.3 33.9 ± 6.1 n.s.
BMI (Kg/m2) 22.5 ± 2.2 22.2 ± 1.6 n.s.
HOMA-IR (pure number) 0.5 ± 0.1 4.0 ± 2.8 p<0.001
Systolic blood pressure (mmHg) 115.4± 11.9 111.7 ± 15.0 n.s.
Diastolic blood pressure (mmHg) 75.4±9.2 75.7± 8.2 n.s.
Total Cholesterol (mg/dl) 208.3±38.3 199.2±32.5 n.s.
HDLc (mg/dl) 65±11.2 57.7±16.9 n.s.
LDLc (mg/dl) 129.44±38.0 124.8±31.6 n.s.
Triglycerides (mg/dl) 69.3±45.8 83.5±54.5 n.s.
hsPCR (mg/l) 0.86±1.0 0.58±0.3 n.s.
Waist (cm) 84.0±7.0 84.4±8.5 n.s.
https://doi.org/10.1371/journal.pone.0182559.t001
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100%, according to a 5-fold cross-validation approach and a permutation test p-value of 0.005
(S2A Table). Fig 1 shows the heat map for the 512 probe expressions in the 20 subjects. Of
these 512 probes, 321 could be mapped to genes (S2B Table reports the 321 genes and the
associated fold change and p-value). KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathway enrichment analysis for the 321 genes showed significant enrichment (Bonferroni
adjusted p-value 0.0187) of the Adrenergic Signaling in CardioMyocytes (ASCM) KEGG path-
way [39–41], of which 9 genes (Table 2), with significantly altered expression in the compari-
son between the IS and the IR groups, are represented in the list of 321. Other 36 KEGG
pathways were identified after functional analysis, among which insulin secretion and T2DM,
but they did not have significant p-value after adjustment. Fig 2 shows the bar charts for the
KEGG pathway annotation, representing the number of genes found in each pathway and the
corrected p-value associated with them.
Fig 1. Heatmap of the 512 probes distinguishing IR and IS subjects. Rank values of the probes are
represented and colors indicate the position of the probe expression level in the ranking of each sample
(ascending order, red for over expressed probes, blue for under expressed probes). Each column reports the
data of a single subject: 1 to 10 are the insulin resistant individuals, 11 to 20 are the insulin sensitive subjects.
See also S2A Table.
https://doi.org/10.1371/journal.pone.0182559.g001
Table 2. Differentially expressed genes associated to the ASCM pathway included in the biomarker. The table provides the list of gene symbols, the
log2 fold-change of gene expression levels between IS and IR subjects and the associated Wilcoxon-test p-values.
Gene symbol Log2FC [IS/IR] p-value direction
ADCY9 -0.295 0.0499 Up regulated in IR
TNNI3 0.213 0.0499 Up regulated in IS
RAPGEF3 -0.085 0.0281 Up regulated in IR
CACNA1S 0.068 0.0104 Up regulated in IS
CACNG3 -0.090 0.0379 Up regulated in IR
ADRA1B 0.095 0.0499 Up regulated in IS
CAMK2D -0.200 0.0499 Up regulated in IR
PPP2R3C 0.174 0.00466 Up regulated in IS
PPP2CA -0.180 0.00466 Up regulated in IR
https://doi.org/10.1371/journal.pone.0182559.t002
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Increasing evidences indicate that in obese subjects mononuclear cells can induce chronic
low-grade inflammation, which develops into insulin resistance and metabolic syndrome
[42]. Then we asked whether the alteration of the ASCM pathway is detected also in over-
weight subjects with high HOMA-IR index. For this reason, from the MultiKnowledge cohort,
we selected other two groups of 10 subjects with different values of HOMA-IR index but with
BMI>25.0 (namely IS-BMI and IR-BMI), and matched for age, sex and BMI, as described in
the methods section (Table 3). Then, we tested whether the expression of some of the genes in
Fig 2. Bar chart of gene enrichment. The bars represent the annotated KEGG pathways within the genes distinguishing between IR and IS subjects. The
Bonferroni corrected p-value is reported on each bar, while the bar color represents the –log10 (p-value) for each term. The bars’ length shows the number of
genes found in each term. The dendrogram on the left represents the term similarity, i.e. terms are connected depending on the number of genes they share.
https://doi.org/10.1371/journal.pone.0182559.g002
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the ASCM pathway could provide a biomarker able to discriminate between the two high BMI
groups.
Of the 96 probes within the ASCM pathway, 16 probes, corresponding to 15 genes, (S3
Table), constituted a biomarker that distinguished IS-BMI group from IR-BMI group with
100% discriminant accuracy and a permutation test p-value of 0.0001 (Fig 3).
Deepening in the gene expression dysregulations of the ASCM pathway, our working
hypothesis was the net functional balance of the differentially expressed genes in this pathway
would predict a cluster of alterations in the IR group, including increased intracellular cAMP
(due to overexpression of ADCY9) and Ca2+ (due to an alteration of the expression of PP2A
Table 3. Anagraphic, anthropometric and clinical characteristics of the high (BMI>25.0) BMI insulin-sensitive (Low HOMA-IR) and insulin-resistant
(High HOMA-IR) groups. N.s.: non-significant.
IS-BMI IR-BMI p-value
Gender (M/F) (n) 6/4 7/3 n.s.
Age (year) 36.70± 4.7 38.10± 6.9 n.s.
BMI (Kg/m2) 27.7± 2.5 27.9 ± 2.7 n.s.
HOMA-IR (pure number) 0.8 ± 0.3 3.1 ± 0.8 p<0.001
Systolic blood pressure (mmHg) 124.0±11.0 122.6 ± 13.7 n.s.
Diastolic blood pressure (mmHg) 77.2±5.5 82.9± 7.0 n.s.
Total Cholesterol (mg/dl) 200.5±38.3 211.5±37.2 n.s.
HDLc (mg/dl) 52.2±8.0 47.3±12.3 n.s.
LDLc (mg/dl) 134.6±31.8 145.1±43.8 n.s.
Triglycerides (mg/dl) 68.4±30.2 119.0±48.7 p<0.05
hsPCR (mg/l) 1.35±0.99 3.0±4.2 n.s.
Waist (cm) 94.40±7.3 98.1±5.0 n.s.
https://doi.org/10.1371/journal.pone.0182559.t003
Fig 3. Network of subject groups in the IS-BMI and IR-BMI study of the ASCM pathway. Networks represent subjects’
classification in the validation study of the ASCM pathway in groups with high BMI (IS-BMI and IR-BMI). Nodes represent
subjects (green ones are IS-BMI subjects, red ones are IR-BMI). The edge length is proportional to the difference between
the subject signatures (short edges indicate high similarities, long edges indicate low similarities, no edge indicates a
negligible similarity). In each case subjects naturally cluster together according to the class they belong to. See also S3
Table.
https://doi.org/10.1371/journal.pone.0182559.g003
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subunits PPP2R3C and PPP2CA) levels and accelerated apoptosis (due to an overexpression of
RAPGEF3). These alterations would seem to depict a scenario in which individuals with “pri-
mary” (i.e. not associated to obesity and/or metabolic syndrome) IR are burdened with “over-
work” (increased intra-cellular cAMP and Ca2+) in excitable cells, together with accelerated
cellular demise. Since IR is a risk factor for T2DM, CHF and AD, diseases in which excitable
cells (beta cells, cardiomyocytes and neurons, respectively) play major roles, we hypothesized
that, if an alteration of the gene expression pattern in the ASCM pathway is associated with the
development of IR, within its genes we should find biomarkers able to distinguish healthy
from diseased also in these conditions.
To test this hypothesis, we investigated whether the genes in the ASCM pathway could be
used to find a biomarker that would distinguish healthy controls from patients with T2DM, or
CHF or AD. As to T2DM, we tested gene expression data of pancreatic beta cells of 10 healthy
donors and 10 T2DM donors from a publicly available dataset (GSE20966 [35]). Of the 418
probes within the ASCM pathway, 52 probes, corresponding to 43 genes (S4A Table), consti-
tuted a biomarker that distinguished controls from patients with 100% discriminant accuracy
according to a 10-fold cross-validation approach and a permutation test p-value of 0.0001
(Fig 4A).
As to CHF (of which IR is a known risk factor), we used two publicly available gene expres-
sion data sets (GSE9128 [36] and GSE21125 [37]) of PBMCs and white blood cells, respectively.
In this case we used two datasets because the number of subjects of the first dataset was too
small to allow the cross-validation of results. From [36] we compared 3 healthy controls versus
4 non-ischemic cardiomyopathy patients. In the gene expression data, 261 probes corresponded
to genes in the ASCM pathway. Among these, 41 probes, corresponding to 37 genes (S4B
Table), constituted a biomarker that distinguished healthy controls from patients with 100%
discriminant accuracy and a permutation test p-value of 0.026 (Fig 4B). From [37] we compared
9 healthy controls versus 9 CHF patients. In the gene expression data 146 probes corresponded
to genes in the ASCM pathway, within which 22 genes (S4C Table) constituted a biomarker
that distinguished controls from patients with 91.7% discriminant accuracy according to a
9-fold cross-validation approach and a permutation test p-value of 0.0015 (Fig 4C).
As to AD, we tested gene expression data of hippocampal cells from a publicly available
dataset (GSE28146, [38]) taken from 8 control donors and 7 AD patients’ autopsies. In this
case, within the 261 probes of the ASCM pathway, 15 genes (S4D Table) constituted a bio-
marker that distinguished controls form patients with 100% discriminant accuracy according
to a 5-fold cross-validation approach and a permutation test p-value of 0.0002 (Fig 4D).
The key findings are summarized in Fig 5.
Discussion
One main finding of this study is the identification of a PBMC transcriptomic signature ex-
clusively associated to IR, independently of age, sex, BMI, waist, blood pressure and lipids. Fig
5 is a concept map, which highlights the principal findings of the paper. These results were
obtained by means of an innovative ranked-based classification method. The transcriptomic
signature of IR included 321 annotated genes, which identified IR and IS subjects with 100%
accuracy. The most representative pathway, and the only one endowed with full statistical
significance, was the "Adrenergic signaling in cardiomyocytes" (ASCM) KEGG pathway,
therefore the best candidate for having a role within IR development. Since alterations in the
ASCM pathway were observed also in overweight/obese subjects with polar opposite level of
HOMA-IR index, gene expressions in this pathway should be directly related to insulin resis-
tance and not a feature related to BMI. At a closer scrutiny, the high IR-BMI group down-
Early molecular mechanism of insulin resistance
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regulates genes involved in the betaA2R signaling (GNAI1 and PI3KCG), decreasing the PI3K
activity [43]. This observation is in line with the insulin sensitizing activity of PI3K and
strongly suggests that the modification of the expression of genes related to this pathway could
be a biomarker of IR. If this hypothesis holds true, the ASCM pathway should harbor biomark-
ers distinguishing between healthy from diseased subjects also in other cases where IR is
known to develop.
Specifically, the differentially expressed genes of the ASCM pathway are involved in the
modulation of the calcium flux across the membranes (CACNA1S, CACNG3, CAMK2D), and
in cell growth and apoptosis (RAPGEF3, PPP2R3C, PPP2CA, TNNI3). After scrutinizing the
alterations in the expression of genes involved in this pathway, we put forward the hypothesis
Fig 4. Networks of subject groups in each replication study of the ASCM pathway. Networks represent
subjects’ classification in the four replication studies of the ASCM pathway as a provider of classification
effective biomarkers of IR-related disorders. Nodes represent subjects (green ones are healthy subjects, red
ones are diseased). The edge length is proportional to the difference between the subject signatures (short
edges indicate high similarities, long edges indicate low similarities, no edge indicates a negligible similarity).
In each case subjects naturally cluster together according to the class they belong to. A: classification of 10
healthy donors and 10 T2DM donors [35]. B: classification of 3 healthy controls versus 4 NICM patients [36].
C: classification of 9 healthy controls versus 9 CHF patients [37], in this case a diseased subject is miss-
classified by the algorithm. D: classification of 8 control donors and 7 AD patients’ autopsies [38]. Networks
were drawn through Cytoscape [40]. See also S4 Table.
https://doi.org/10.1371/journal.pone.0182559.g004
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that they should lead to an increase in intracellular cAMP and calcium and to accelerated apo-
ptosis and impaired cell growth in the IR group. These processes are extremely relevant in dis-
orders of excitable cells, among which IR is believed to play a significant role in T2DM (beta
cells), CHF (cardiomyocytes) and AD (neurons).
Thus, we investigated whether the ASCM pathway gene expression profile could distinguish
affected individuals from healthy controls, i.e. we tried to replicate the role of the pathway
investigating whether it would contain biomarkers of IR-related disorders. For this purpose
we applied a ranked-based classification method to validate our findings and found that the
ASCM gene expression profile could provide molecular biomarkers of all the above mentioned
conditions (Fig 5).
With hindsight, these results are not surprising. For instance, as to T2DM, it is well known
that calcium plays a key role in the process of glucose-induced insulin release of the pancreatic
Fig 5. Block diagram reassuming the results of the paper. Starting from the MultiKnowledge population we identified a cohort of 10+10 subjects with
normal BMI and opposite HOMA-IR value. We computed a biomarker able to discriminate between the two groups and we identified the ASCM pathway as
the most significant pathway in the biomarker. We then validated this result in another cohort from the MultiKnowledge study of 10+10 subjects with BMI>25
and opposite HOMA-IR value. Finally, we identified genes in the ASCM able to discriminate between healthy controls and patients with T2DM, or CHF, or
AD.
https://doi.org/10.1371/journal.pone.0182559.g005
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beta cell [44]. Mice with chronic activation of CAMK2 in beta cells developed glucose into-
lerance and abnormal insulin secretion through a ryanodine receptor 2 (Ryr2) dependent
mechanism. Chronic activation of Ryr2 was also implicated in beta cell apoptosis [45]. In the
T2DM biomarker herein reported, CALML3, CALML5 and CAMK2B genes are up regulated
in the patients, possibly leading to an aberrant activation of RyRs. Studies in diabetic rat and
human samples have shown that RyRs activity can be regulated during acute hyperglycemia in
cardiomyocytes [46]. Moreover, it was demonstrated that sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) activity and calcium content are reduced in myocytes of a mouse model of
diabetes (db/db mice), and similarly in glucose intolerant rats [47, 48].
Also in the case of CHF, a biomarker derived from the ASCM pathway was able to dis-
criminate between patients and controls, in both CHF gene expression data sets. According to
our results in IR vs IS, the adrenergic receptor signaling via cAMP-dependent and indepen-
dent pathways may be overactive and it is known that high intracellular calcium levels, one of
the main features of CHF, result into increased apoptosis. In different rat models of IR, the
decreased SERCA activity is caused by a slowed cytosolic Ca2+ removal [49], which leads to
alterations of the excitation–contraction coupling process. Finally, IR is present in non-dia-
betic CHF patients with both reduced and preserved ejection fraction [50].
Also in the AD case a number of differentially expressed genes of the ASCM pathway could
distinguish patients from controls. Aberrant intracellular calcium signaling occurs in the early
stage of AD, and elevated cytosolic calcium concentrations correlate with amyloid precursor
protein production [51]. Recent studies showed that IR and the associated key risk factors
(such as obesity and physical inactivity) are associated with both brain changes and an in-
creased risk of developing dementia or AD [52]. Moreover, in mouse models of AD the expres-
sion of RyRs is up-regulated in neurons [53].
Thus, these replication studies confirm that the ASCM pathway gene expression profile
provides biomarkers of IR and IR-related conditions and that ASCM plays a role in the patho-
genic processes put in motion by “primary” IR. To this regard, it is to be highlighted that in
our study the ASCM pathway was selected in otherwise healthy subjects, with normal BMI and
clinical parameters, and in cells (PBMC) that are not classical targets of insulin action, are
exposed to all cues circulating in the blood stream and express about 80% of the overall ge-
nome. Thus, our findings strongly suggest a very early and widespread involvement of the
ASCM pathway in the pathogenesis of IR and related conditions. The putative functional alter-
ations brought about by the IR related changes in the ASCM pathway can be predicted to be
particularly relevant in excitable cells, such as pancreatic beta cells, myocytes and neurons. The
ASCM pathway, therefore, could be (one of) the molecular basis of vulnerability of excitable
cells secondary to, or concomitant with, the onset of IR.
It could be argued that within the list of genes distinguishing IR and IS subjects, the canoni-
cal candidates that are usually altered in IR are missing, such as some inflammatory genes,
insulin receptors or glucose channels. On one side we can say that there are a few genes within
the list that are indeed ascribable to IR, such as RIMS2 which has a role in insulin secretion
[54], SLC2A2 (GLUT2, a glucose channel [55], up-regulated in IS), IRS4 (insulin receptor sub-
strate 4 [56], up-regulated in IR) and IL4, (up-regulated in IS). On the other hand, it must be
kept in mind that the analyzed subjects are healthy and young individuals, it is therefore not
surprising that a massive alteration is not detected in the gene expression profile, but rather a
somewhat softened signal which is to be attributed to mechanisms generally diffused in the
organism and early in the history of IR development.
It could be argued that a comparison between two groups of 10 subjects each cannot reach
the proper statistical power. However, this is due to the fact that we made a very closed match
between the subjects in each group in order to avoid confounding effects of the principal
Early molecular mechanism of insulin resistance
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features involved in the onset of IR. This type of approach is consistent with other previous
papers [57, 58]. To overcome the problem, when possible, classification accuracy of computed
biomarkers has been evaluated according to a state-of-the-art cross-validation scheme and by
computing permutation test p-values that in all cases confirmed the statistical significance of
the analysis (see Results and Methods sections). Moreover, we also confirmed our results in
another well matched population of 20 subjects, thus increasing the effectiveness of the overall
analysis, which finally considers 40 subjects in total.
One main limitation of this study is the lack of a post-hypothesis specific experimental
investigation. Although our results derive from solid microarray data, the connection to spe-
cific protein activity cannot be abstracted, for instance because of post-translational modifica-
tion. Therefore the herein generated hypothesis would need further support from targeted
proteomics examination in healthy and diseased states.
We conclude that modifications in the gene expression profile of the ASCM pathway are a
very early molecular signature of “primary” IR and that the gene expression profile of this
same pathway provides biomarkers of several IR-related conditions. Corollaries of the findings
herein reported are that the ASCM pathway could provide a common molecular pathogenetic
platform for IR-related disorders as diverse as T2DM, CHF and AD and that the early molecu-
lar signature of IR could be an important aid in the efforts aiming at preventing, early detecting
and optimally treating IR-related diseases.
Methods
Study subjects
The study population included 148 apparently healthy volunteers selected among the offspring
of the Barilla study population [12, 59]. The Barilla study is a longitudinal observational survey
performed in 732 factory workers of the Barilla factory since 1981 with a follow up of 15 years.
In 2007–2008 we launched another observational study with the preferential recruitment of
the offspring of the participants of the Barilla Study, naming it Multiknowledge study. The
general aim of this study was to select and to investigate novel potential biomarkers of the car-
diometabolic risk, with specific attention devoted to the phenotype of hyperinsulinemia/insu-
lin resistance. Exclusion and inclusion criteria of the Multiknowledge study were extensively
described in previous reports [60, 61]. Briefly, Caucasian subjects from both genders between
18 and 60 years of age were enrolled. They underwent medical history collection and physical
examination, including smoking habits, blood pressure and anthropometric measurements.
After an overnight fast, a venous blood sample was drawn for complete blood cell count, stan-
dard clinical chemistry and other measurements for companion experiments, including 50 ml
of blood in an EDTA BD Vacutainer tube (Becton Dickinson and Company, Franklin Lakes,
NJ, US) for isolation of circulating PBMC (see below for further details). Subsequently, a stan-
dard oral glucose tolerance test (OGTT) (75 g of glucose administered orally) was performed
in all subjects and plasma glucose and serum insulin levels were measured to assess glucose tol-
erance. Complete data for this report were available in 148 subjects.
This study was reviewed and approved by the Institutional Ethical Committee "Comitato
Etico per Parma". All subjects were informed about the aims and the potential risks of the
study and signed a written, informed consent. The main demographic, anthropometric and
humoral features of the study cohort are reported in S1 Table.
Since the Multiknowledge Study is a purely observational survey with a non-trial design,
according to the policy of the International Committee of Medical Journal Editors (ICMJE),
registration of the Multiknowledge Study in a public trials registry is not required (http://
Early molecular mechanism of insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0182559 August 4, 2017 11 / 18
www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-
registration.html).
Assessment of insulin sensitivity/resistance and selection of insulin-
sensitive and insulin-resistant groups
HOMA-IR was calculated using the formula:
HOMAIR ¼
fasting glucose  fasting insulin
22:5
ð1Þ
in which glucose units are mmol/l and insulin units are mU/l.
After excluding all subjects with BMI25.0, we selected 10 subjects from the bottom range
(IS group) and 10 subjects from the top range (IR group) of the HOMA-IR distribution, with
the additional goal of matching the two groups also for anthropometry, sex, blood pressure,
triglycerides and HDL-cholesterol, i.e. the phenotypes of the metabolic syndrome. Selected fea-
tures of the IS and IR groups are reported in Table 1.
A second selection was made in order to validate the results found in the first two groups
(IS and IR). We selected from the same cohort all subjects with BMI>25.0 and, similarly to the
first selection, we choose 10 subjects with the lowest HOMA-IR index (IS-BMI) and 10 sub-
jects with the highest HOMA-IR index (IR-BMI). Both groups are matched for the principal
anthropometry and clinical variables. Selected features of the IS-BMI and IR-BMI groups are
reported in Table 3.
Gene expression profiling of circulating lympho-monocytes
The PBMC transcriptome profile was assessed in IR and IS groups. PBMCs were immediately
isolated by density gradient centrifugation (Lymphoprep, Sentinel Diagnostic, Milan, Italy),
washed three times with PBS 1% FBS and then stored as a dry pellet at—80˚C. Total RNA was
isolated using column separation (RNeasy Mini Kit, Qiagen, Valencia, CA, US), followed by
DNase treatment to avoid DNA contamination, according to the manufacturer’s instructions.
RNA was then eluted with RNase-free water and stored at -80˚C until hybridization.
Quality control testing of extracted RNA was performed before hybridization. Total RNA
yield was checked using a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA). RNA quality was assessed measuring the 28S/18S rRNA and
the RNA Integrity Number (RIN) with a Bioanalyzer 2100, using RNA 6000 Nano Chips (Agi-
lent Technologies, Santa Clara, CA, USA).
The gene expression microarray protocol was as previously described [62]. Briefly, a total of
500 ng of each RNA sample was reversely transcribed into cDNA and then amplified and la-
belled with Cy5 dye. The same amount of RNA from a commercially-available pool of human
leucocyte total RNA (Clontech, Mountain View, CA, USA) was used as reference. Reference
and sample RNA were hybridized together on 4X44 Whole Human Genome Agilent Microar-
ray slides (Agilent Technologies, ref. G4112F). Dye-normalized, background-subtracted log-
ratios of sample to reference expression were calculated using Agilent’s Feature Extraction
Software v8.0. Hybridization quality was checked using the software’s quality report. We vali-
dated transcriptomic analysis by these methods in a previous paper [62].
Statistical and bioinformatics analyses
All descriptive statistics are reported as mean ± SD, unless otherwise specified. The distribu-
tions of anthropometric and humoral parameters were tested by the Kolmogorov-Smirnov test
to detect significant deviations from Gaussian distribution. If needed, log-transformation was
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applied to reduce/correct non-Gaussian distributions. Between-group comparisons were per-
formed on normal variables using Student’s t-test. Statistical analysis for these clinical parame-
ters was performed using software package SPSS 15.0 for Windows (SPSS Inc., Chicago, IL,
US), except for the gene expression data which were read and cleaned by means of the R Bio-
conductor package Limma [63–65]. The functions readTargets and read.maimages were used
to read the files. The backgroundCorrect function was used for background correction using
the method “normexp”. Normalization within arrays and between arrays was performed with
the functions normalizeWithinArrays (method “loess”) and normalizeBetweenArrays (method
“quant”). The function avereps was used to average replicate probes, bringing the expression
data set from 45015 to 41001 probes. Probe to gene mapping was achieved through Agilent
annotation supporting files, BioMart [66], Gene cards [67], Aceview [68] and BLAST [69]. Data
can be accessed at GEO (Gene Expression Ominbus) under the accession number GSE87005.
Biomarkers were identified by means of an enhanced version of the rank-based classification
method proposed in [33, 34]. The method, extended with a global optimizer to compute the sig-
natures providing the best sample classification according to genetic optimization, has been
already successfully used [70, 71] and demonstrated to be a very efficacious tool during the SBV
IMPROVER Diagnostic Signature Challenge, an international competition designed to assess
and verify computational approaches for classifying clinical samples based on gene expression
[72]. The method summarizes the characteristics of each sample through a rank-based signature
of probes and then performs an all-to-all signature comparison by means of a distance metric
based on weighted enrichment score (ES) [73, 74]. The results of the comparison are then col-
lected in a distance matrix, which is used to classify samples into different groups by assigning
each sample to the class whose elements have the lowest averaged distance. Moreover, to assess
the reliability of the analysis, classification accuracy is computed, when possible, according to a
cross-validation approach and its statistical significance is evaluated by a permutation test com-
paring the obtained classification accuracy with the accuracy of an empirical distribution
obtained by 10000 random permutations of the probe labels. Finally, a biomarker is extracted
considering the union of the probes included in at least one sample signature.
Cytoscape and the ClueGO plug in were used [40, 75] for gene annotation/gene enrichment
analysis of KEGG pathways [41]. A Bonferroni step-down corrected p-value threshold of 0.05
was employed to declare the statistical significance of gene enrichment.
The above procedure was applied in a “reverse” fashion in the replication studies, the goal
of which was to assess whether the ASCM pathway could provide statistically significant, clas-
sification effective biomarkers also in cells/organs/tissues taken from individuals with insulin-
resistant conditions. After selecting all genes of the ASCM pathway, the algorithm was applied
to test whether the pathway was significantly perturbed, more specifically whether some of its
genes could form a biomarker, which would correctly classify patients and controls. For the
second selection (BMI>25.0) and for each of the 4 datasets available in the scientific literature,
a classification effective biomarker was found entirely made of genes belonging to the ASCM
pathway. The statistical significance of the performance of these biomarkers was assessed by
permutation tests (S3 and S4 Tables).
Cytoscape [40] was also used to draw the networks reported in Figs 3 and 4. In particular,
the Edge-Weighted Force-Directed network layout (BioLayout) was used to arrange the place-
ment of nodes according to subject distances. The R package ggplot2 was used for Fig 2.
Supporting information
S1 Table. General characteristics of the study cohort. The table represents the main charac-
teristics of the subjects of Multi-Knowledge study. Data are reported as mean±standard
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deviation.
(PDF)
S2 Table. A, B. Features of the biomarker with statistically significant separation property
between insulin-resistant and insulin-sensitive healthy individuals. S2A Table: for each one
of the 512 probes included in the biomarker, the probe ID, the associated gene symbol (when
available, see S1B Table), the log2 fold-change of the gene expression level between IS and IR
individuals and the associated Wilcoxon-test p-value are reported; S2B Table: the 321 bio-
marker features out of 512 for which a probe ID to gene symbol mapping is available. The list
provides probe IDs, gene symbols, log2 fold-change of gene expression levels and associated
Wilcoxon-test p-values between IS and IR.
(XLSX)
S3 Table. Validation biomarker extracted from the ASCM pathway that can discriminate
between IS-BMI and IR-BMI groups. The list provides probe IDs, gene symbols, log2 fold-
change of gene expression levels between IS-BMI and IR-BMI individuals and their associated
Wilcoxon-test p-values.
(XLSX)
S4 Table. A, B, C, D. Validation biomarkers extracted from the ASCM pathway that can
discriminate healthy individuals from patients with IR-related conditions. S4A Table: list
of probe IDs, gene symbols, log2 fold-change of gene expression levels and associated t-test p-
values in discriminating beta cells of patients with type 2 diabetes from healthy non diabetic
individuals; S4B Table: list of probe IDs, gene symbols, log2 fold-change of gene expression
levels and associated t-test p-values in discriminating PBMC of patients with non-ischemic
cardiomyopathy from healthy non diabetic individuals; S4C Table: list of probe IDs, gene sym-
bols, log2 fold-change of gene expression levels and associated t-test p-values in discriminating
white blood cells of patients with chronic heart failure from healthy non diabetic individuals;
S4D Table: list of probe IDs, gene symbols, log2 fold-change of gene expression levels and asso-
ciated t-test p-values in discriminating hippocampal cells of patients with Alzheimer disease
from healthy non diabetic individuals.
(XLSX)
Author Contributions
Conceptualization: Alessandra Dei Cas, Diego Ardigò, Ivana Zavaroni, Riccardo C.
Bonadonna.
Data curation: Eleonora Derlindati, Valentina Spigoni.
Formal analysis: Alice Matone, Luca Marchetti, Barbara Montanini.
Funding acquisition: Alessandra Dei Cas, Ivana Zavaroni, Riccardo C. Bonadonna.
Investigation: Eleonora Derlindati, Valentina Spigoni.
Project administration: Ivana Zavaroni, Riccardo C. Bonadonna.
Supervision: Riccardo C. Bonadonna.
Validation: Alice Matone, Eleonora Derlindati, Luca Marchetti.
Visualization: Alice Matone, Luca Marchetti.
Writing – original draft: Alice Matone, Eleonora Derlindati, Luca Marchetti.
Writing – review & editing: Corrado Priami, Riccardo C. Bonadonna.
Early molecular mechanism of insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0182559 August 4, 2017 14 / 18
References
1. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion
and resistance. Am J Physiol. 1979; 237 (3): 214–223.
2. Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin
resistance in humans: a dose-response study. Metabolism. 1990; 39 (5): 452–459. PMID: 2186255
3. Bonadonna RC, Groop LC, Simonson DC, DeFronzo RA. Free fatty acid and glucose metabolism in
human aging: evidence for operation of the Randle cycle. Am J Physiol. 1994; 266 (3 Pt 1): 501–509.
4. Nuutila P, Knuuti MJ, Maki M, Laine H, Ruotsalainen U, Teras M, et al. Gender and insulin sensitivity in
the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes. 1995; 44 (1):
31–36. PMID: 7813811
5. Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K, et al. Insulin sensitivity
index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young
healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J
Clin Invest. 1996; 98 (5): 1195–1209. https://doi.org/10.1172/JCI118903 PMID: 8787683
6. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Population-based incidence
rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004; 53 (7):
1782–1789. PMID: 15220202
7. Bonadonna RC, Stumvoll M, Fritsche A, Muggeo M, Haring H, Bonora E, et al. Altered homeostatic
adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes:
studies with a minimal model to assess beta-cell function. Diabetes. 2003; 52 (2): 470–480. PMID:
12540623
8. Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Virkamaki A. Elevated fasting insulin
concentrations associate with impaired insulin signaling in skeletal muscle of healthy subjects indepen-
dent of obesity. Diabetes Metab Res Rev. 2002; 18 (3): 209–216. https://doi.org/10.1002/dmrr.272
PMID: 12112939
9. Irving BA, Nair KS, Srinivasan M. Effects of insulin sensitivity, body composition, and fitness on lipopro-
tein particle sizes and concentrations determined by nuclear magnetic resonance. J Clin Endocrinol
Metab. 2011; 96 (4): E713–718. https://doi.org/10.1210/jc.2010-2170 PMID: 21270325
10. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance
in essential hypertension. N Engl J Med. 1987; 317 (6): 350–357. https://doi.org/10.1056/
NEJM198708063170605 PMID: 3299096
11. Bonadonna RC. The Syndrome of Insulin Resistance and its Links to Atherosclerosis. In: R.A.
DeFronzo, E. Ferrannini, H. Keen & P. Zimmet eds., John Wiley & Sons Ltd, Chichester, England.
"International Textbook Of Diabetes Mellitus", 3rd Edition; vol. 2: 1379–1394, 2004
12. Zavaroni I, Bonora E, Pagliara M, Dall’Aglio E, Luchetti L, Buonanno G, et al. Risk factors for coronary
artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med.
1989; 320 (11): 702–706. https://doi.org/10.1056/NEJM198903163201105 PMID: 2646537
13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365 (9468): 1415–1428.
https://doi.org/10.1016/S0140-6736(05)66378-7 PMID: 15836891
14. Alberti KGMM Eckel RH, Grundy SM Zimmet PZ, Cleeman JI Donato KA, et al. Harmonizing the Meta-
bolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epi-
demiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;
World Heart Federation; International. Circulation. 2009; 120 (16): 1640–1645. https://doi.org/10.1161/
CIRCULATIONAHA.109.192644 PMID: 19805654
15. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint state-
ment from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia. 2005; 48 (9): 1684–1699. https://doi.org/10.1007/s00125-005-1876-2 PMID: 16079964
16. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, et al. Insulin effects on glucose
metabolism, memory, and plasma amyloid precursor protein in Alzheimer’s disease differ according to
apolipoprotein-E genotype. Ann N Y Acad Sci. 2000; 903: 222–228. PMID: 10818510
17. Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Bjornholm M, Heinonen OJ, et al. Insulin signalling
and resistance in patients with chronic heart failure. J Physiol. 2003; 550 (Pt 1): 305–315. https://doi.
org/10.1113/jphysiol.2003.042648 PMID: 12740426
18. Parsonage W, Hetmanski D, Cowley A. Differentiation of the metabolic and vascular effects of insulin in
insulin resistance in patients with chronic heart failure. Am J Cardiol. 2002; 89 (6): 696–703. PMID:
11897212
19. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 dia-
betes. Hepatology. 2014; 59 (2): 713–723. https://doi.org/10.1002/hep.26672 PMID: 23929732
Early molecular mechanism of insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0182559 August 4, 2017 15 / 18
20. Cersosimo E, Triplitt C, Mandarino LJ, DeFronzo RA. Pathogenesis of Type 2 Diabetes Mellitus. De
Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Endo-
text. 2000.
21. Haeusler RA, Hartil K, Vaitheesvaran B, Arrieta-Cruz I, Knight CM, Cook JR, et al. Integrated control of
hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun. 2014;
5: 5190. https://doi.org/10.1038/ncomms6190 PMID: 25307742
22. Talchai C, Xuan S, Lin H V, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of
diabetic beta cell failure. Cell. 2012; 150 (6): 1223–1234. https://doi.org/10.1016/j.cell.2012.07.029
PMID: 22980982
23. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, et al. Insulin/Foxo1 pathway regulates
expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004; 279 (29):
30817–30822. https://doi.org/10.1074/jbc.M402367200 PMID: 15123605
24. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin
sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 2001; 108 (9): 1359–1367. https://doi.
org/10.1172/JCI12876 PMID: 11696581
25. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of lipo-
protein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001; 98(13): 7522–
7527. https://doi.org/10.1073/pnas.121164498 PMID: 11390966
26. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically
reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006; 147 (3): 126–132.
https://doi.org/10.1016/j.lab.2005.10.005 PMID: 16503242
27. Yamaoka M, Maeda N, Nakamura S, Mori T, Inoue K, Matsuda K, et al. Gene expression levels of S100
protein family in blood cells are associated with insulin resistance and inflammation (Peripheral blood
S100 mRNAs and metabolic syndrome). Biochem Biophys Res Commun. 2013; 433 (4): 450–455.
https://doi.org/10.1016/j.bbrc.2013.02.096 PMID: 23501102
28. Bouchard-Mercier A, Paradis AM, Rudkowska I, Lemieux S, Couture P, Vohl MC. Associations between
dietary patterns and gene expression profiles of healthy men and women: a cross-sectional study. Nutr
J. 2013; 12: 24. https://doi.org/10.1186/1475-2891-12-24 PMID: 23398686
29. Castaner O, Corella D, Covas MI, Sorli J V, Subirana I, Flores-Mateo G, et al. In vivo transcriptomic pro-
file after a Mediterranean diet in high-cardiovascular risk patients: a randomized controlled trial. Am J
Clin Nutr. 2013; 98 (3): 845–853. https://doi.org/10.3945/ajcn.113.060582 PMID: 23902780
30. Myhrstad MC, Ulven SM, Gunther CC, Ottestad I, Holden M, Ryeng E, et al. Fish oil supplementation
induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in periph-
eral blood mononuclear cells: a transcriptomic approach. J Intern Med. 2014; 276 (5): 498–511. https://
doi.org/10.1111/joim.12217 PMID: 24641624
31. Rudkowska I, Ponton A, Jacques H, Lavigne C, Holub BJ, Marette A, et al. Effects of a supplementation
of n-3 polyunsaturated fatty acids with or without fish gelatin on gene expression in peripheral blood
mononuclear cells in obese, insulin-resistant subjects. J Nutrigenet Nutrigenomics. 2011; 4 (4): 192–
202. https://doi.org/10.1159/000330226 PMID: 21876360
32. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model
assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies
in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23
(1): 57–63. PMID: 10857969
33. Lauria M. Rank-based miRNA signatures for early cancer detection. Biomed Res Int. 2014; doi: https://
doi.org/10.1155/2014/192646 PMID: 25054131
34. Lauria M, Moyseos P, Priami C. SCUDO: a tool for signature-based clustering of expression profiles.
Nucleic Acids Res. 2015; 43 (W1): W188–192. https://doi.org/10.1093/nar/gkv449 PMID: 25958391
35. Marselli L, Thorne J, Dahiya S, Sgroi DC, Sharma A, Bonner-Weir S, et al. Gene expression profiles of
Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes.
PLoS One. 2010; 5 (7): e11499. https://doi.org/10.1371/journal.pone.0011499 PMID: 20644627
36. Cappuzzello C, Napolitano M, Arcelli D, Melillo G, Melchionna R, Di Vito L, et al. Gene expression pro-
files in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics. 2009; 38
(3): 233–240. https://doi.org/10.1152/physiolgenomics.90364.2008 PMID: 19336532
37. Smih F, Desmoulin F, Berry M, Turkieh A, Harmancey R, Iacovoni J, et al. Blood signature of pre-heart
failure: a microarrays study. PLoS One. 2011; 6 (6): e20414. https://doi.org/10.1371/journal.pone.
0020414 PMID: 21731613
38. Blalock EM, Buechel HM, Popovic J, Geddes JW, Landfield PW. Microarray analyses of laser-captured
hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer’s dis-
ease. J Chem Neuroanat. 2011; 42 (2): 118–126. https://doi.org/10.1016/j.jchemneu.2011.06.007
PMID: 21756998
Early molecular mechanism of insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0182559 August 4, 2017 16 / 18
39. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge
and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014; 42 (Database issue): D199–205.
https://doi.org/10.1093/nar/gkt1076 PMID: 24214961
40. Smoot ME, Ono K, Ruscheinski J, Wang P- L, Ideker T. Cytoscape 2.8: new features for data integra-
tion and network visualization. Bioinformatics. 2011; 27 (3): 431–432. https://doi.org/10.1093/
bioinformatics/btq675 PMID: 21149340
41. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28
(1): 27–30. PMID: 10592173
42. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011; 29:415–
445. https://doi.org/10.1146/annurev-immunol-031210-101322 PMID: 21219177
43. Beretta M, Bauer M, Hirsch E. PI3K signaling in the pathogenesis of obesity: The cause and the cure.
Adv Biol Regul. 2015; 58:1–15. https://doi.org/10.1016/j.jbior.2014.11.004 PMID: 25512233
44. Rorsman P, Braun M, Zhang Q. Regulation of calcium in pancreatic α- and β-cells in health and disease.
Cell Calcium. 2012; 51 (3–4): 300–308. https://doi.org/10.1016/j.ceca.2011.11.006 PMID: 22177710
45. Dixit SS, Wang T, Manzano EJQ, Yoo S, Lee J, Chiang DY, et al. Effects of CaMKII-mediated phos-
phorylation of ryanodine receptor type 2 on islet calcium handling, insulin secretion, and glucose toler-
ance. PLoS One. 2013; 8 (3): e58655. https://doi.org/10.1371/journal.pone.0058655 PMID: 23516528
46. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, et al. Diabetic hyperglycaemia activates
CaMKII and arrhythmias by O-linked glycosylation. Nature). 2013; 502 (7471): 372–376.
47. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in
diabetic db/db mouse heart. Diabetes. 2004; 53 (12): 3201–3208. PMID: 15561951
48. Pereira L, Ruiz-Hurtado G, Rueda A, Mercadier J- J, Benitah J- P, Gómez AM. Calcium signaling in dia-
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